International Journal of Preventive Medicine (Int J Prev Med)2008-78021272021101824972497ENDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome20211017Dear Editor, There are potential laboratory biomarkers that can be used to ascertain the severity and progression of coronavirus disease 2019 (COVID‑19), thereby predicting the survival of COVID‑19 patients. For instance, there were rises in the levels of C‑reactive protein (CRP), serum amyloid A, interleukin‑6 (IL‑6), lactate dehydrogenase, neutrophil‑to‑lymphocyte ratio, D‑dimer, cardiac troponin, and renal biomarkers (Urea and creatinine levels;) in COVID‑19 patients, and monitoring these biomarkers is important in defining the severity and progression of COVID‑19 among these patients.http://ijpm.mui.ac.ir/index.php/ijpm/article/view/2497http://ijpm.mui.ac.ir/index.php/ijpm/article/download/2497/717718337